Background: Vaccines were developed to stop the pandemic stage of COVID-19. A wide range of adverse effects, including vascular complications, has been reported after vaccination. Up to now, various studies have reported different rates of myocardial infarction (MI) after COVID-19 vaccination. So, this meta-analysis and systematic review study was designed to estimate the pooled incidence of MI after COVID-19.
Methods: Two experienced researchers conducted searches in various databases and sources such as EMBASE, Scopus, Web of Science, Google Scholar, PubMed and gray literature, including references from studies published before March 2023. They collected information on participant count, the number of individuals who experienced MI after vaccination, average age, vaccine type, primary author, publication year and country of origin.
Results: A total of 385 articles were revealed by a literature search, and for further evaluation, 248 studies remained after removing duplicates. Seven articles remained for meta-analysis. Three studies provided the number of controls and the incidence of MI in both vaccinated and non-vaccinated groups. The incidence of MI after COVID-19 vaccines was ignorable (0%, I=99%, P<0.001). After COVID-19 vaccines, the odds of MI were 0.99 (95% CI 0.84-1.18) (I=0, p=0.9).
Conclusion: As shown by the results of the present meta-analysis and systematic review, the incidence of MI after COVID-19 vaccination can be ignorable and the risk was not increased by vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11565153 | PMC |
| http://dx.doi.org/10.26574/maedica.2024.19.3.587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The potential impact of inflammation on the lipid paradox in patients with acute myocardial infarction: a multicenter study.
BMC Med
December 2024
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167, Beilishi Rd, Beijing, 100037, Xicheng District, China.
Background: Low-density lipoprotein cholesterol (LDL-C) is a well-recognized risk factor for cardiovascular diseases. However, several clinical studies demonstrated an inverse association between LDL-C and mortality risk in patients with acute myocardial infarction (AMI), known as the lipid paradox. This study aims to investigate the potential impact of inflammation on the association between LDL-C levels and mortality risks.
View Article and Find Full Text PDFIntracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
Am Heart J
December 2024
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München; DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany.
Background: Percutaneous coronary intervention of severely calcified lesions is limited by inadequate stent expansion and poor clinical outcomes. Over the past decade, several devices and techniques have been developed for calcium modification and lesion preparation. Intravascular lithotripsy (IVL) is a novel tool in this context.
View Article and Find Full Text PDFALKBH5 promotes cardiac fibroblasts pyroptosis after myocardial infarction through Notch1/NLRP3 pathway.
Cell Signal
December 2024
Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan, China. Electronic address:
Through bioinformatics screening, we previously found that AlkB homolog 5 (ALKBH5) expression, an mA demethylase, was higher in patients with heart failure than in the normal population. This study aimed to investigate the molecular mechanisms by which ALKBH5 regulates heart failure. We established a myocardial infarction (MI)-induced heart failure model in rats in vivo and an in vitro hypoxia model using rat primary cardiac fibroblasts (RCFs).
View Article and Find Full Text PDFHealth disparities in diabetes treatment: The challenge of G6PD deficiency.
Diabetes Res Clin Pract
December 2024
Leumit Research Institute, Leumit Health Services, Tel-Aviv, Israel; Adelson School of Medicine, Ariel University, Ariel, Israel.
Aims: To assess the impact of Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an enzymatic deficiency prevalent in individuals of African or Asian descent, on Hemoglobin A1c (HbA1c) levels, diabetes medication purchases, and the cumulative incidence of diabetes related complications.
Methods: A large cohort study was conducted within a national health organization, comparing 3,913 G6PD-deficient patients to a matched control group without G6PD deficiency over two decades. The main measures and outcomes were the HbA1c levels, patterns of diabetes medication purchases, and the incidence of severe diabetes-related complications.
ANTI-THROMBOTIC STRATEGY FOR THE MANAGEMENT OF NONOCCLUSIVE THROMBUS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN YOUNG PATIENTS - ANTARTICA STUDY.
Indian Heart J
December 2024
Apollo Institute of Medical Sciences and Research, Jubilee Hills, Film Nagar, Hyderabad, Telangana, 500090.
Introduction: Various cardiovascular thrombo-embolic clinical entities use combined ATS for prevention and treatment. After PCI, AF patients are typically prescribed DOAC, DAPT/SAPT, as component of ATS to minimize stroke risk and treat pulmonary embolism and venous thromboembolism. Some small observational studies have shown that a combined ATS can clear small thrombi in LV dysfunction and/or apical aneurysms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!